The Effects of Ezetimibe/Simvastatin Versus Simvastatin Alone on Platelet and Inflammatory Biomarkers in Patients With the Metabolic Syndrome.

Trial Profile

The Effects of Ezetimibe/Simvastatin Versus Simvastatin Alone on Platelet and Inflammatory Biomarkers in Patients With the Metabolic Syndrome.

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Dec 2014

At a glance

  • Drugs Ezetimibe/simvastatin (Primary) ; Simvastatin
  • Indications Metabolic syndrome
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 12 Jun 2012 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.
    • 12 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Oct 2009 Planned end date changed from 1 Jun 2010 to 1 Jan 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top